Search a title or topic

Over 20 million podcasts, powered by 

Player FM logo
Artwork

Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Determining the Cause and Severity of Sepsis with a Point-of-Care Test

37:09
 
Share
 

Manage episode 523546173 series 3323646
Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Sepsis remains one of medicine’s most intractable and costly problems, arising when an infection triggers a runaway immune response that damages organs long after a pathogen is controlled. It accounts for an estimated $53 billion in Medicare spending alone, yet more than a hundred drug trials have failed to yield a single approved drug that directly treats the underlying immune dysfunction. Inflam­matix, which grew out of work at Stanford University, has developed a point-of-care blood test to determine whether an infection is bacterial or viral, as well as the severity of the patient’s immune response to optimize treatment. We spoke to Tim Sweeney, CEO of Inflammatix, about the company’s TriVerity test for sepsis, how it works, and how it is used in an ER setting to determine who needs antibiotics, ICU‑level care, or a broader diagnostic workup.​

  continue reading

593 episodes

Artwork
iconShare
 
Manage episode 523546173 series 3323646
Content provided by Levine Media Group. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Levine Media Group or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://podcastplayer.com/legal.

Sepsis remains one of medicine’s most intractable and costly problems, arising when an infection triggers a runaway immune response that damages organs long after a pathogen is controlled. It accounts for an estimated $53 billion in Medicare spending alone, yet more than a hundred drug trials have failed to yield a single approved drug that directly treats the underlying immune dysfunction. Inflam­matix, which grew out of work at Stanford University, has developed a point-of-care blood test to determine whether an infection is bacterial or viral, as well as the severity of the patient’s immune response to optimize treatment. We spoke to Tim Sweeney, CEO of Inflammatix, about the company’s TriVerity test for sepsis, how it works, and how it is used in an ER setting to determine who needs antibiotics, ICU‑level care, or a broader diagnostic workup.​

  continue reading

593 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Copyright 2025 | Privacy Policy | Terms of Service | | Copyright
Listen to this show while you explore
Play